I do not know if the pps is selling off due to Novavax's comment in the article but the last thing investors want to hear is an executive stating that a particular shot should provide protection against other variants. No one wants Novavax to repeat the error of last year where they positioned themselves using their original booster instead of reformulating to an omicron booster vaccine.
The only thing investors want to hear coming from Novavax is that they will have the recommended FDA booster and ON TIME.
Now if Flip wants to make an argument that their vaccine offers greater protection against other variants than the other vaccines than show the data and give your commercial team a competitive edge.